Login to Your Account

Other News To Note

Tuesday, March 22, 2011
OxiGene Inc., of South San Francisco, is weighing the next steps for developing Zybrestat as a potential treatment for anaplastic thyroid cancer (ATC), following a Type C meeting with the FDA. Data from the company's FACT trial showed that nearly 24 percent of the 84 ATC patients treated with Zybrestat (fosbretabulin) survived one year or longer, compared with a historical rate of less than 10 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription